Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model

a.
Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
b.
Department of Pathology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
c.
Department of Pharmacology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China

More Information

Corresponding author: E-mail address: hbzhang2006@gmail.com (Hongbing Zhang)

摘要

- /
- /
- /
- /
Abstract: Tuberous sclerosis complex (TSC) is an autosomal dominant tumor syndrome which afflicts multiple organs and for which there is no cure, such that TSC patients may develop severe mental retardation and succumb to renal or respiratory failure. TSC derives from inactivating mutations of either the TSC1 or TSC2 tumor suppressor gene, and the resulting inactivation of the TSC1/TSC2 protein complex causes hyperactivation of the mammalian target of rapamycin (mTOR), leading to uncontrolled cell growth and proliferation. Recent clinical trials of targeted suppression of mTOR have yielded only modest success in TSC patients. It was proposed that abrogation of a newly identified mTOR-mediated negative feedback regulation on extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway and on the well-documented RTK-PI3K-AKT signaling cascade could limit the efficacy of mTOR inhibitors in the treatment of TSC patients. Therefore, we speculate that dual inhibition of mTOR and ERK/MAPK pathways may overcome the disadvantage of single agent therapies and boost the efficacy of mTOR targeted therapies for TSC patients. Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouseTsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059. When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.
- TSC /
- mTOR /
- ERK/MAPK /
- rapamycin /
- PD98059

HTML全文

参考文献(31)

[1]	Bissler, J.J., McCormack, F.X., Young, L.R. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N. Engl. J. Med., 358 (2008),pp. 140-151
[2]	Brachmann, S., Fritsch, C., Maira, S.M. et al. PI3K and mTOR inhibitors—a new generation of targeted anticancer agents Curr. Opin. Cell Biol., 21 (2009),pp. 1-5
[3]	Carracedo, A., Ma, L., Teruya-Feldstein, J. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J. Clin. Invest., 118 (2008),pp. 3065-3074
[4]	Castro, A.F., Rebhun, J.F., Clark, G.J. et al. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner J. Biol. Chem., 278 (2003),pp. 32493-32496
[5]	Chan, J.A., Zhang, H., Roberts, P.S. et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation J. Neuropathol. Exp. Neurol., 63 (2004),pp. 1236-1242
[6]	Cloughesy, T.F., Yoshimoto, K., Nghiemphu, P. et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med., 5 (2008),p. e8
[7]	Crino, P.B. Do we have a cure for tuberous sclerosis complex? Epilepsy Curr., 8 (2008),pp. 159-162
[8]	Crino, P.B., Nathanson, K.L., Henske, E.P. The tuberous sclerosis complex N. Engl. J. Med., 355 (2006),pp. 1345-1356
[9]	Curatolo, P., Bombardieri, R., Jozwiak, S. Tuberous sclerosis Lancet, 372 (2008),pp. 657-668
[10]	Dabora, S.L., Jozwiak, S., Franz, D.N. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs Am. J. Hum. Genet., 68 (2001),pp. 64-80
[11]	Davies, D.M., Johnson, S.R., Tattersfield, A.E. et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis N. Engl. J. Med., 358 (2008),pp. 200-203
[12]	Ehninger, D., Han, S., Shilyansky, C. et al. Nat. Med., 14 (2008),pp. 843-848
[13]	El-Hashemite, N., Zhang, H., Henske, E.P. et al. Lancet, 361 (2003),pp. 1348-1349
[14]	Engelman, J.A., Chen, L., Tan, X. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat. Med., 14 (2008),pp. 1351-1356
[15]	Garami, A., Zwartkruis, F.J., Nobukuni, T. et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 Mol. Cell, 11 (2003),pp. 1457-1466
[16]	Grant, S. Cotargeting survival signaling pathways in cancer J. Clin. Invest., 118 (2008),pp. 3003-3006
[17]	Harrington, L.S., Findlay, G.M., Gray, A. et al. J. Cell. Biol., 166 (2004),pp. 213-223
[18]	Inoki, K., Li, Y., Xu, T. et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling Genes Dev., 17 (2003),pp. 1829-1834
[19]	Kinkade, C.W., Castillo-Martin, M., Puzio-Kuter, A. et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J. Clin. Invest., 118 (2008),pp. 3051-3064
[20]	Kuang, Y.H., Chen, X., Su, J. et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion Cancer Lett., 276 (2009),pp. 189-195
[21]	Kwiatkowski, D.J., Zhang, H., Bandura, J.L. et al. Hum. Mol. Genet., 11 (2002),pp. 525-534
[22]	Lee, L., Sudentas, P., Donohue, B. et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models Genes Chromosomes Cancer, 42 (2005),pp. 213-227
[23]	Manning, B.D., Cantley, L.C. AKT/PKB signaling: Navigating downstream Cell, 129 (2007),pp. 1261-1274
[24]	Paul, E., Thiele, E. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis N. Engl. J. Med., 358 (2008),pp. 190-192
[25]	Potter, C.J., Pedraza, L.G., Xu, T. Akt regulates growth by directly phosphorylating Tsc2 Nat. Cell. Biol., 4 (2002),pp. 658-665
[26]	Serra, V., Markman, B., Scaltriti, M. et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res., 68 (2008),pp. 8022-8030
[27]	Shah, O.J., Wang, Z., Hunter, T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr. Biol., 14 (2004),pp. 1650-1656
[28]	Stommel, J.M., Kimmelman, A.C., Ying, H. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science, 318 (2007),pp. 287-290
[29]	Tee, A.R., Manning, B.D., Roux, P.P. et al. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb Curr. Biol., 13 (2003),pp. 1259-1268
[30]	Zhang, H., Bajraszewski, N., Wu, E. et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR J. Clin. Invest., 117 (2007),pp. 730-738
[31]	Zhang, H., Cicchetti, G., Onda, H. et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR J. Clin. Invest., 112 (2003),pp. 1223-1233